Recent Advances of UCSF NewCos 

 

Akili

 

Status:

$301 Million value
Privately held company

Find out more:

The First FDA-Approved Video Game Was Developed in San Francisco

 

Status:

$6.3 Million value
Publicly traded company

Find out more:

Alessa Therapeutics Announces IND Clearance to Collaborate with the National Cancer Institute

 

Status:

$300 + Million value
Privately held company

Find out more:

Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development

eFFector

 

Status:

$160 Million value
Publicly traded company

Find out more:

eFFECTOR Debuts as Publicly Traded Next-Generation Oncology Company

 

Status:

$345 Million value
Publicly traded company

Find out more:

Erasca Announces Collaboration with Pfizer

fortis

 

Status:

$58 Million value
Privately held company

Find out more:

Fortis Therapeutics, a UCSF Founded Startup, Closes $40 Million Series A Financing

Nerona

 

Status:

$148 Million value
Privately held company

Find out more:

Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

Pliant

 

Status:

$160 Million value
Publicly traded company

Find out more:

Pliant Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial

Sana

 

Status:

$700 Million value
Publicly traded company

Find out more:

Sana Biotechnology Shows Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates